Jaguar Health (JAGX) is up more than 400% in Monday's regular session after the company announced it received fee waivers from the U.S. Food and Drug Administration, a development that could ease financial pressures on the small pharmaceutical company.

What Happened

Jaguar Health disclosed on September 22, 2026 that it obtained fee waivers from the FDA. The announcement, released during the trading session, triggered a massive surge in the biotech's share price, moving from a prior close of $2.67 to a session high of $13.48.

The stock became the session's biggest gainer by a wide margin, with more than 6.8 million shares changing hands compared to the stock's average daily volume of roughly 152,000 shares.

Why the Fee Waivers Matter

Fee waivers from the FDA can reduce the financial burden on small pharmaceutical companies that are working to bring drugs through the approval process. For a company like Jaguar Health, which employs just 49 people and carries a tiny market capitalization, regulatory-related costs can represent a significant portion of operating expenses.

The waiver announcement comes as Jaguar continues developing its lead product, Crofelemer, for multiple indications. The drug is already marketed as Mytesi for diarrhea relief in adults with HIV/AIDS, and the company is pursuing additional uses including cancer therapy-related diarrhea, rare pediatric conditions like microvillus inclusion disease (MVID), and supportive care for inflammatory bowel diseases.

Context: Recent Developments

The FDA news follows several other catalysts for JAGX:

  • A reverse stock split announced on September 15, 2026, a common move among low-priced stocks working to meet exchange listing requirements
  • Positive updates on the pivotal pediatric trial for Crofelemer in MVID with intestinal failure
  • Commercial launch of Neonorm Dog, the company's over-the-counter gastrointestinal product for dogs, available on Amazon

Key Metrics

  • Session move: +404.87%
  • Last price: $13.48
  • Prior close: $2.67
  • Session volume: 6,895,134 shares (approximately 45x average daily volume)
  • Market cap: ~$911,000
  • Float: 55,020 shares

What to Watch

JAGX remains an extremely low-priced, highly speculative stock with a market cap under $1 million. The company has historically struggled with stock price compliance and has used reverse splits to maintain listing. Today's surge dramatically increases volatility and risk. Any follow-up news or lack of detail in the FDA waiver announcement could lead to sharp reversals.

Investors should note that while fee waivers can improve a company's cash position, they do not change the fundamental challenge of advancing drug candidates through clinical trials and regulatory review.